

ORAL SESSIONS

09.00–10.30

11.00–12.30

PL4 Plenary: Consequences of an Evolving Epidemic H P

Chairs: Michael H. Merson, Heydee Pellegrini
 Venue: Arena
 Time: 09.00–10.30

- 485 From personal to global survival
Javier Luis Hourcade Belloque
- 486 From personal to global survival
Naisiadet Maina
- 487 Priorities for public funds: crises in national leadership?
Omwony Ojwok
- 488 Priorities for public funds: crises in national leadership?
Marina Mahathir
- 489 Human rights: consequences for the epidemic HIV
Mary Robinson

PPL4 Plenary: Biomedical Advances in HIV Research

Chairs: Kim Nichols, F. Waldvogel
 Venue: Session Hall I
 Time: 09.00–10.30

- 490 How viruses cause immunosuppression
Rolf Zinkernagel
- 491 The significance of virus subtypes for epidemiology and pathogenesis
Jaap Goudsmit
- 492 How HIV functions, multiplies and causes disease: possible new approaches to therapy
Robert Gallo

A41 Vaccine Trials in Humans P

Chairs: Vina Churdboonchart, Andrei Kozlov
 Venue: Session Hall VII
 Time: 11.00–12.30

- 493 Vaccine trials in humans
Larry Corey
- 494 Induction of immune responses
Kent Weinhold
- 495 CD8+ CTL induced in AIDS vaccine evaluation group phase I trials using canarypox vectors (ALVAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost 21192
Thomas Evans; L. Corey; M.L. Clements-Mann; K. Weinhold; R.B. Belshe; J.L. Excler; A.M. Duliege, USA*
- 496 A phase I trial of vaccinia-env/gag/pol (TBC-3B) given by alternative routes, boosted with rgp120 21199
Michael C. Keefer; M.J. McElrath; K. Weinhold; G.J. Gorse; M. Mulligan; D. Francis; D. Panicali, USA*
- 497 HIV-1 cross-clade lymphoproliferative responses following immunization with recombinant Gp120 SF2 21201
Thippawan Chuenchitra; S. Ratto-Kim; M. De Souza; K. Rungruengthanakit; S. Nitayaphan; C. Khamboonruang; C. Chuenchitra; R.A. Michael; F. Sinangil; A.M. Duliege; J.G. McNeil; D.L. Birx, Thailand*
- 498 NIAD funding opportunities for AIDS vaccine research: new strategy and programmes
Steve Bende

NOTES

B41 Care in Special Populations

Chairs: Shaun Mellors, Robert Shearer

Venue: Session Hall III

Time: 11.00–12.30

- 499 Virologic response to antiretroviral therapy among HIV-infected injection drug users 32407
*Wafaa El-Sadr**; Sharon Mannheimer; J. Flowers; H. Safavi; J. Curtis, USA
- 500 Barriers to HIV antiretroviral therapy among injection drug users in settings with and without universal health insurance coverage 42285
*David Celentano**; R.S. Hogg; D. Vlahov; S.A. Strathdee; R.D. Moore; A. Palepu; S. Cohn, USA
- 501 Prisons and public health: Emerging issues in HIV treatment adherence 32408
Linda Frank, USA
- 502 Continuity of medical care and risk of incarceration in HIV+ and HIV- high risk women 32411
*Mary Sheu**; Timothy Flanigan; T.P. Flanigan; J. Allsworth; J. Hogan; M.D. Stein; D. Vlahov; E. Schoenbaum, USA
- 503 Health status and co-morbidity of HIV+ and HIV- out-of-treatment injection drug users (IDUs) 32409
*Frederick Altice**; K. Khooshnood; K.M. Blankenship; C.T. Roan; M. Kravitz, USA
- 504 Pozfit, positively fit: A prospective, pilot project in community-based HIV rehabilitation services 42400
*Gerry Bally**; G.R. Murphy, Canada
- 505 Palliative care for HIV-infection in a skilled nursing facility 22427
*Peter A. Selwyn**; K.P. Fennie; S. Molde; J. Constantino, Sr.; P. Wetherill; L. Goldman; C. Kennedy, USA

B42 Predictors of Response to Antiretroviral Treatment 

Chairs: Jonathan Anderson, Peter Mugenyi

Venue: Session Hall IV

Time: 11.00–12.30

- 506 HIV RNA, CD4+ cell count, and immune activation markers predict HIV-related wasting prior to AIDS in the Multicenter AIDS Cohort Study (MACS) 32167
*Robert H. Lyles**; A.M. Tang; J.W. Mellors; J.B. Margolick; B.R. Visscher; J.P. Phair; N.M.H. Graham, USA
- 507 HIV serum RNA, CD4 cell numbers and risk for clinical endpoints in a case-cohort study of ACTG 175 12124
*David Katzenstein**; S. Kim; M. Hughes; S. Hammer; V. Degruittola, USA
- 508 Phosphorylation rate of 3'-azidothymidine in maternal and fetal peripheral blood mononuclear cells at term 42258
*Riad Agbaria**; J. Barak; E. Manor; J. Balzarini, Israel
- 509 Zidovudine (ZDV) phosphorylation determined at intervals over 12 months in naive and antiretroviral experienced HIV+ patients 42260
*P.G. Hoggard**; David J. Back; S.E. Gibbons; J. Lloyd; M.G. Barry; S.H. Khoo; C. Loveday, UK
- 510 The rate of decline of HIV-1 RNA in plasma correlates with nelfinavir concentrations in plasma 42259
*Richard M.W. Hoetelmans**; M.H.E. Reijers; G.F. Weberling; S. Furriaans; F.M.A. Lange, The Netherlands
- 511 Plasma concentrations of saquinavir (SQV) determine HIV-1 RNA response over a 48-week period 42261
*Richard M.W. Hoetelmans**; R.P.G. Heeswijk, Van; P.L. Meenhorst; F.W. Mulder; W.A. Scheele; F.H. Beijnen, The Netherlands
- 512 Saliva as a possible specimen for monitoring compliance and plasma levels in patients treated with indinavir (IDV) 32330
*Patricia W.H. Hugen**; D.M. Burger; R.M.W. Hoetelmans; K. Brinkman; P.L. Meenhorst; J.W. Mulder; P.P. Koopmans, The Netherlands

B43 HIV-infection in Children 

Chairs: Luke Chipperfield, Connie Mwaise Osborne

Venue: Arena

Time: 11.00–12.30

- 513 Markers for diagnosis and for monitoring therapy in children 43555
John Ziegler
- 514 Clinical management in the North 13212
Sandra Burchett
- 515 Clinical management in resource-poor settings 13212
Suniti Solomon
- 516 Palliative care for children 13212
Jim Oleske

C41 Trends and Patterns of HIV Epidemics 

Chairs: Jordi Casabona, Euclides Castilho

Venue: Session Hall V

Time: 11.00–12.30

- 517 HIV-infection in young men in Northern Thailand, 1991–1997, increasing role of injection drug use 43555
*Kenrad Nelson**; S. Eiutrakul; D.D. Celentano; C. Beyrer; S. Kuntolbutra; C. Khamboonruang, USA
- 518 Epidemiology of HIV-1 seroconversion among young adults in the U.S. Army, 1985–1996: Current trends in an evolving epidemic 13212
*Philip Renzullo**; H. Bacellar; R.P. Garner; D.L. Birx; J.G. McNeil, USA
- 519 Risk for HIV-1 seroconversion in the Ugandan people's defense forces 23507
*Kathleen George**; D. Hom; J. McGrath; J.L. Johnson; P. Mugenyi; R. Mugenwa; J. Ellner, Uganda
- 520 Annual HIV incidence decreased among persons with sexually transmitted diseases (STD) in Italy between 1988 and 1994 13281
*Barbara Suligoi**; M. Giuliani; M. Balducci; N. Galai, Italy
- 521 HIV in the Philippines: Analysis of data from the National HIV Sentinel Surveillance System 43508
*Maria Consoria Lim-Quizon**; M.C.R. Roces; W. Cuenco; A.E. Ghee; G. Pomerol; S. Omi, Philippines
- 522 The HIV/AIDS epidemic in Europe: Changing trends and new challenges 13179
*Francoise F. Hamers**; A.M. Downs; A. Infuso; J.B. Brunet, France

ORAL SESSIONS

11.00–12.30

11.00–12.30

C42 STD/HIV Interaction **G**
 Chairs: Subhash Hira, Judy Wasserheit
 Venue: Session Hall VI
 Time: 11.00–12.30

- 523 Overview of the STD-HIV interaction
King Holmes
- 524 Population attributable risk of HIV incidence associated with STD symptoms, Rakai Community-Based Study, Uganda
*Maria J. Wawer**; *N.K. Sewankambo*; *D. Serwadda*; *L. Paxton*; *N. Kivanuka*; *C.J. Li*; *R.H. Gray, USA* 23372
- 525 STD control for HIV prevention in the US: Is there likely to be an impact?
*William Kassler**; *K.L. Irwin*; *M.L. Kamb*; *H. Weinstock*; *R.W. Steketee*; *M. St. Louis*; *J. Wasserheit, USA* 33238
- 526 Estimating the effect of treating sexually transmitted diseases (STDs) on HIV transmission
*Richard Rothenberg**; *J. Wasserheit*; *M. St. Louis, USA* 23369
- 527 Heterosexual and perinatal transmission of HIV-1: Associations with bacterial vaginosis (BV)
*Taha Taha**; *N. Kumwenda*; *G. Liomba*; *J. Chipangwi*; *D. Hoover*; *G. Dallabetta*; *P. Mioti, USA* 23347
- 528 A randomized trial of STD control during pregnancy in Rakai, Uganda: Impact on maternal and infant health
*Ronald H. Gray**; *G. Kingozi*; *F. Wabwire-Mangen*; *D.S. Serwadda*; *C. Li*; *M. Meehan*; *M.J. Wawer, USA* 23276

C43 Rapid Assessment for Intervention Development

 Chairs: Thierry E. Mertens, Gerald V. Stimson
 Venue: Satellite Hall 2000
 Time: 11.00–12.30

- 529 Rapidly responding to HIV and AIDS – Can social science inform community and international interventions?
*Chris Fitch**; *G.V. Stimson*; *T. Rhodes*; *A. Ball*; *G. Weiler*; *R. Sujata*; *A. Morue*; *A. Perez-Gomez, UK* 24178
- 530 Mekong movements: Border areas HIV/AIDS prevention project
*Gioi Tran Minh**; *L.A. Esposito Catherine*; *O. Souksavanh, Vietnam* 43237
- 531 Situation analysis of prostitution in Bobo Dioulasso, Burkina Faso and vulnerability of the sex workers in the context of the HIV epidemic
*Michel Cartoux**; *P. Huygens*; *M.D. Nikiema*; *G. Ido*; *A. Dembele*; *P. Van De Perre, Burkina Faso* 43290
- 532 Effectiveness of peer education and monitoring of the condom use by the sex workers in brothel settings in Bangladesh for prevention of HIV
*Ankhi Begum**; *M.A. Ouddus*; *F.K. Chowdh Ury*; *Swarup Sarkar*; *M. Bloem*; *Nazrul Islam, Bangladesh* 33521
- 533 Peer education to reduce STI/HIV transmission in Mutare, Zimbabwe
*Simon Mashababe**; *D. Mclean*; *R. Gomo*; *D. Wilson*; *R. Sabatier, Zimbabwe* 33516

D41 Human Rights and Legal Challenges **G H**
 Chairs: Ian Kramer, Miriam Maluwa
 Venue: Session Hall I
 Time: 11.00–12.30

- 534 Developing the human rights program for the AIDS prevention council in Jalisco, Mexico
*Armando J. Diaz Camarena**; *Jesus Martinez Serna*; *Juana Martinez Lopez*; *Ancira Dueñas Martinez*; *Carmen Cardona Aldrete*; *Patricia Campos Lopez, Mexico* 44145
- 535 Training HIV-positive people to document human rights violations in Asia: The APN+ human rights initiative
*Susan Paxton**; *B. White, Australia* 44133
- 536 Access to treatment: AIDS affected population in Costa Rica wins constitutional challenge
*Antonio Matamoros**; *L.G.M. Murillo Guillermo*; *M.F.G. Garita Manuel*; *M.C.R. Marco Castillo, Costa Rica* 44104
- 537 Promoting the rights of prisoners: Condoms, bleach, needles, methadone and care in prisons
Ralf E.F. Jürgens, Canada 44191
- 538 A human rights approach to reducing women's vulnerability to HIV/AIDS
Daniel Whelan, USA 44148
- 539 Creation of an enabling and gender just legal environment as a prevention strategy for the spread of HIV/AIDS amongst women
Mandeep Dhaliwal, India 44164

D42 Workplace – Promotion, Prevention and Protection

 Chairs: Richard Constant Okuv, Anthony Pramvalratana
 Venue: Session Hall II
 Time: 11.00–12.30

- 540 Peer education among factory workers in Zimbabwe; providing a sustainable HIV prevention intervention
*David Katzenstein**; *W. McFarland*; *M. Mbizvo*; *A. Latif*; *R. Machekano*; *J. Parsonnet*; *M. Bassett, USA* 33514
- 541 AIDS, India and the trucking industry
*Barun Kanjilal**; *S. Forsythe, India* 44200
- 542 Protecting paradise: Tourism and AIDS in the Dominican Republic
*Steven Forsythe**; *J. Hasbún*; *M. Butler De Lister, UK* 44239
- 543 UK coalition back to work pilot project
Bec Clarkson, UK 24288
- 544 Sexual networking and AIDS awareness program at the workplace: the case of oil locations in Nigeria
*Bode-Law Faleyimu**; *O.A. Fagade*; *S.O. Ogunniti*; *A.I. Faleyimu*; *L.A. Ubuane, Nigeria* 43230
- 545 Grief at work: helping organizations cope with AIDS-related loss
*Stuart Gibson**; *A. Plotnick*; *D. Scott, USA* 24243

Skills Building workshops 11.00–14.30: see page 00 for details

NOTES

A42 Animal Models for Vaccine Development

Chairs: Sam Avrett, Reinhard Kurth

Venue: Session Hall III

Time: 13.00–14.30

- 546 Attenuated SIV vaccines: Safety and efficacy following heterologous challenge 11238
*Mark G. Lewis**; F. Novembre; R. Desrosiers; Y. Lu; E. Rud; V. Hirsch; D. Bix, USA
- 547 Role of b-chemokines in protective immunity against intrarectal SIVsm challenge of macaques 11239
*Rigmor Thorstensson**; R. Ahmed; C. Wilson; P. Putkonen; Y. Wang; T. Lehner; G. Biberfeld, Sweden
- 548 Recombinant vaccine-induced protection against the highly pathogenic SIVmac251 dependence on route of challenge exposure 21200
Genevoffa Franchini, USA
- 549 Protective T-cell mediated immunity induced by a consecutive HIV-1 DNA and avipox vaccine regimen 21198
*Stephen Kent**; A. Zhao; E.M. Dax; J.D. Chandler; H.L. Robinson; D.B. Boyle; I.A. Ramshaw, Australia
- 550 Potent neutralization of primary HIV-1 isolates by antisera induced upon immunization with a recombinant protein expressing the native V1/V2 domain of gp120 21194
*Abraham Pinter**; O. Trochev; W.J. Honnen; Z. Wu; S. Reiken; M. Lewis; S.C. Kayman, USA
- 551 Multi-subtype envelope-based DNA and protein immunization strategies for broadening immune responses to HIV-1 21196
*Susan W. Barnett**; Y. Sun; H.S. Legg; T.C. VanCott; J.R. Mascola; F.M. Sinangil, USA

A43 Pre-Clinical Drug Development

Chairs: D.J. Back, T. Smart

Venue: Session Hall VII

Time: 13.00–14.30

- 552 Introduction
J. Condra
- 553 S-1153, a new nonnucleoside reverse transcriptase inhibitor of HIV-1 41181
*Tamio Fujiwara**; A. Sato; M. El-Farrash; Y. Wu3; L. Chen; M. Hatanaka; Y. Hinuma, Japan
- 554 Cellular pharmacology of the antiviral agents PMPA and PMEAs in vitro and in vivo 41175
*Arnold Fridland**; B. Robbins; J. Rodman; C.C. Tsai; N. Bischofberger, USA
- 555 A resistance surmountable HIV protease inhibitor effective against both wild-type and new analogs of HIV-1 protease 41212
*Yoshiaki Kiso**; M. Kishida; H. Matsumoto; S. Mizumoto; T. Kimura, Japan
- 556 Abacavir (1592, ABC) prevents spread of HIV-1 in brain tissue of SCID mice with HIV-1 encephalitis 11233
*Jenae Limoges**; D.R. McClernon; Y. Persidsky; J. Rasmussen; E.R. Lanier; J. Reinhard; H.E. Gendelman, USA
- 557 Anti-HIV activity, biochemistry, and pharmacokinetics of b-D-2',3'-didehydro-2',3'-dideoxy-5- fluorocytidine (D-D4FC) 41174
*Raymond Schinazi**; L. Ma; J. Shi; D. Liotta; A. Faraj; J.P. Sommadossi, USA

B44 Neurological Complications of HIV

Chairs: Paola Cinque, Christina M. Marra

Venue: Session Hall IV

Time: 13.00–14.30

- 558 Latest developments in neuropathogenesis
To be confirmed
- 559 Animal models of HIV neuropathogenesis
Dominique Dormont
- 560 Predictive markers for HIV-associated dementia and sensory neuropathy 32191
*Elizabeth Childs**; Justin C. McArthur; R.H. Lyles; E. Miller; B.A. Cohen; B.B. Chen; J. Mellors; J.C. McArthur, USA
- 561 Safety and efficacy of abacavir (ABC, 1592) in AIDS dementia complex (Study CNAB 3001) 32192
*Bruce James Brew**; S.J. Brown; J. Catalan; N. Sacktor; M. Halman; W.T. Symonds; C. Romero; CNAB 3001 Study Team, Australia
- 562 Progressive multifocal leukoencephalopathy (PML) treatment with cidofovir 32193
*Rustam Al-Shahi**; M. Sadler; E. Davies; M.R. Nelson; B.G. Gazzard, UK
- 563 Evidence for independent development of RT inhibitor (RTI) resistance patterns in cerebrospinal fluid (CSF) compartment 32284
*Phillip Cunningham**; D. Smith; C. Satchell; D.A. Cooper; B.J. Brew, Australia
- 564 Stavudine stops neuro-AIDS in AZT-non-responders 32207
*Gabriele Arendt**; H.-J. v. Giesen; H. Jablonowski, Germany

B45 Bridging Session: Issues in Clinical Trial Design

Chairs: Lynda Dee, Markus Flepp

Venue: Arena

Time: 13.00–14.30

- 565 What kinds of trials?
Ann Collier
- 566 The role of cohort studies
Andrew Phillips
- 567 Trials in developing countries
Praphan Phanuphak
- 568 The patients' perspective
James Kreppner

C44 Transgender Issues: Living with HIV, Prevention, Identity		G
Chairs: Camille Cabral, Julian Hows		
Venue: Session Hall V		
Time: 13.00–14.30		
569	Implications of living with HIV/AIDS as a transitioning transsexual woman <i>Danny Anderson, Canada</i>	14208
570	HIV-infection among transsexual sex workers from developing countries. A review of six years of activity of a reference center in Rome <i>Laura Spizzichino*; P. Gattari; M. Zaccarelli Mauro; S. Venezia; G. Rezza, Italy</i>	23534
571	The HIV hormone bridge: Connecting impoverished HIV+ transsexual sex workers to HIV medical care <i>James Grimaldi*; J. Jacobs, USA</i>	44225
572	The health care issues of the HIV+ and HIV- incarcerated transgendered community <i>Scott Cozza, USA</i>	43417
573	The Portuguese transgender community: an unknown reality <i>Maria José Campos*; Jo Bernardo; G. Machado; G. Tavares; K. Wandolly; G. Salce, Jr.; G. Diniz, Portugal</i>	43267
574	Mobilizing transgenders for HIV prevention through cultural presentation <i>Jose Sescun*; Alfeo Salcedo, Philippines</i>	23530

C45 Model-Based Evaluation of HIV Prevention Programmes		
Chairs: Jane Galvao, Edward Kaplan		
Venue: Session Hall VI		
Time: 13.00–14.30		
575	Patterns of participation in mass STD treatment: Model-aided evaluation of impact on HIV incidence <i>Eline Korenromp*; C. Van Villet; A. Gavyole; H. Grosskurth; R.H. Hayes; J.D.F. Habbema, The Netherlands</i>	43476
576	Potential public health impact of offering post-exposure prophylaxis (PEP) for episodic high-risk sexual behaviour by men who have sex with men (MSM) <i>Grant Colfax*; E. Vittinghoff; K. MacQueen; J. Douglas; D. McKirnan; F. Judson; S. Buchbinder, USA</i>	33183
577	The effects of two years of harm reduction in Rome <i>Marina Davoli*; Annette Verster; Teresa Spadea; Fabio Patrino; Fulvia Pascualini; Carlo Alberto Perucci; Massimo Arcá, Italy</i>	33391
578	Cost effectiveness of an HIV/AIDS peer education programme among commercial sex workers (CSW): results from Cameroon <i>Lilani Kumaranayake*; P. Mangtani; A. Boupda-Kuate; J.C. Foumena Abada; C. Cheta; Z. Njournemi; Watts, UK</i>	33592
579	Interaction of vaccine effectiveness and risky behaviour <i>Sally Blower</i>	
580	HIV counselling and testing in Tanzania and Kenya is cost-effective: Results from the voluntary HIV counselling and testing study <i>Michael Sweat*; G. Sangiwa; D. Balmer, USA</i>	33277

C46 HIV and Drug Injection: A World of Epidemics		G
Chairs: Genci Mucollari, Swarup Sarkar		
Venue: Satellite Hall 2000		
Time: 13.00–14.30		
581	Outbreaks of HIV-infections among Russian injecting drug users <i>Irena Savchenko, Russia</i>	
582	HIV/AIDS risk in non-hospitalized injection drug users in Japan <i>Timothy Sankary*; H. Ohashi; K. Soda, USA</i>	23183
583	Trend of HIV incidence among drug users in an HIV epicenter in Northern Thailand, 1989–1997 <i>Somsak Supawitkul*; P. Saksoong; P. Sawanpanyalert; S. Piyaworawong; H. Yanai, Thailand</i>	23198
584	Decline in a very large HIV epidemic: Injecting drug users in New York City, 1991–1996 <i>Don C. Des Jarlais*; R. Friedman Samuel; Theresa Perlis; Deren Sherry; Lucia Torian; Denise Paone; Michael Marmor, USA</i>	23216
585	HIV prevalence among female injecting drug users (IDU) in London, 1990 to 1996 <i>Ali Judd*; G.M. Hunter; G.V. Stimson, UK</i>	23214

D43 What We Are Told About AIDS: Media Response and Transformation

Chairs: Bunmi Makinwa, Simon Watney		
Venue: Session Hall I		
Time: 13.00–14.30		
586	Media impact/agreement between a NGO and a national newspaper. A successful experience of collaboration <i>Alejandro Brito*; A. Diaz; C. Bonfil; M. Figueroa; M. Zozaya, Mexico</i>	34219
587	Sensitizing print media to AIDS and reproductive health issues <i>Sadhna Mohan, India</i>	33447
588	Developing a nationwide public service advertising on STD syndromes <i>Kathleen Cabal*; J. Fleras; C. Aquino; N. Villar, Philippines</i>	33450
589	Using ethnic media to reach multiple language migrant communities in the Sydney region <i>Tadgh McMahon, Australia</i>	33445
590	Assessment of Moscow press participation in HIV/AIDS prevention <i>Elena V. Lioubaeva*; Vadim V. Pokrovsky, Russia</i>	33449
591	Trends of reporting on HIV/AIDS and mobile groups in the print media of Bangladesh. Can the media be an ally in altering the image of AIDS? <i>Joachim Victor Gomes*; Elora Barua; M. Bloem, Bangladesh</i>	34215

NOTES

C47 Tuberculosis and HIV in Developing Countries		
Chairs:	Peter Godfrey-Faussett, Nkanda Luo	
Venue:	Session Hall IV	
Time:	15.00–17.00	
609	The impact of HIV on transmission of tuberculosis (TB) in Ugandan households <i>David Guwatudde*</i> ; <i>M.K. Nakeeto</i> ; <i>P. Musoke</i> ; <i>C. Whalen</i> ; <i>G. Bukonya</i> ; <i>A. Okwera</i> ; <i>J. Ellner</i> , Uganda	13258
610	Trends of HIV-1 infection among pulmonary tuberculous adults, 1993–1997, Kampala, Uganda <i>Alphonse Okwera*</i> ; <i>H. Luzze</i> ; <i>P. Nsubuga</i> ; <i>J.L. Johnson</i> ; <i>C. Whalen</i> ; <i>R. Mugerwa</i> ; <i>J. Ellner</i> , Uganda	13273
611	Increasing frequency of TB among staff in a South African hospital: Impact of the HIV epidemic on supply of health care <i>David Wilkinson*</i> ; <i>C.F. Gilks</i> , South Africa	13246
612	Multiple tuberculosis episodes in HIV-infected individuals: Is there a need for secondary chemoprophylaxis? <i>Samuel E. Kalluvya*</i> ; <i>E.N. Mkombo</i> ; <i>M. Shindano</i> , Tanzania	13277
613	The impact of HIV-infection on tuberculosis control: A prospective cohort study of African patients <i>Pamela Sonnenberg*</i> ; <i>J. Murray</i> ; <i>S.C.P. Shearer</i> ; <i>P. Godfrey-Faussett</i> , South Africa	13259
614	Evaluating community contribution to effective tuberculosis care in high HIV prevalence populations <i>Dermot Maher*</i> ; <i>E. Nyarko</i> , Switzerland	13276
615	Multidrug resistant TB (MRTB): Study of an outbreak in HIV patients <i>Oscar GarciaMecina*</i> ; <i>M. Ambroggi</i> ; <i>G. Ortega</i> ; <i>S.M. Oliva</i> ; <i>L. Redini</i> ; <i>S. Poggi</i> ; <i>J. Benetucci</i> , Argentina	13274
616	HIV-infection and TB associated with injecting drug use and resistant M.tb, Bangkok, Thailand 2HIV/AIDS Collaboration, Nonthaburi; 3CDC & HIV/AIDS Collaboration, Nonthaburi; Thailand <i>Juree Punnotok*</i> ; <i>U. Pumprug</i> ; <i>T. Naiwatanakul</i> ; <i>N. Shaffer</i> ; <i>P. Supannachat</i> ; <i>C. Choochotthaworn</i> ; <i>P. Ponglertnapagorn</i> , Thailand	13264

B46 HIV-Associated Neoplasia G		
Chairs:	Alexandra M. Levine, Andres Schmilovich	
Venue:	Session Hall VII	
Time:	15.00–17.00	
617	Effect of highly active antiretroviral treatment (HAART) in patients with AIDS-associated Kaposi's sarcoma (KS) <i>Sara Santambrogio*</i> ; <i>A.L. Ridolfo</i> ; <i>N. Tosca</i> ; <i>M. Galli</i> ; <i>C. Parravicini</i> ; <i>M. Corbellino</i> , Italy	22275
618	Topical 9-cis-Retinoic acid PanretinT gel as treatment of cutaneous AIDS-related Kaposi's sarcoma: Interim results of an international, placebo-controlled trial (ALRT 1057-503) <i>Neil Bodsworth*</i> ; <i>On Behalf of the International Panretin KS Study Group Intern</i> , Australia	22277
619	North American phase 3 study (protocol L1057T-31) of PanretinT gel (LGD1057, ALRT1057) for cutaneous AIDS-related Kaposi's sarcoma <i>Alvin Frie Dman-Kien*</i> ; <i>M. Conant</i> , USA	22283
620	HHV-8, proliferation, apoptosis and ploidy in epidemic (AKS), endemic (EKS), and classical (CKS) Kaposi's sarcoma (KS) <i>Epahata Kaaya*</i> ; <i>Peter Biberfeld</i> ; <i>E. Castanous-Velez</i> ; <i>T. Heden</i> ; <i>M. Stuzl</i> ; <i>J.Z. Zou</i> ; <i>J.N. Kittinya</i> , Sweden	22282
621	Association of vitamin A deficiency with cervical dysplasia in the Women's Interagency HIV Study (WIHS) <i>Audrey French*</i> ; <i>M.H. Cohen</i> ; <i>R.O. Semba</i> ; <i>J.K. Burke</i> ; <i>K.M. Weber</i> ; <i>L.S. Massad</i> , USA	22301
622	Case-control study of cervical cancer and HIV-infection in Abidjan, Côte d'Ivoire <i>Georgette Adjorlolo-Johnson*</i> ; <i>A. Anhoux</i> ; <i>K. Toure-Coulibaly</i> ; <i>G. Laruche</i> ; <i>G. Aissi</i> ; <i>E. Unger</i> ; <i>M. Honde</i> ; <i>S. Vernon</i> ; <i>A.E. Greenburg</i> ; <i>S.Z. Wiktor</i> , Côte d'Ivoire	22305
623	Incidence of squamous intraepithelial lesions (SIL) in HIV-infected women <i>Marie-Christine Delmas*</i> ; <i>A. Agarossi</i> ; <i>C. Bergeron</i> ; <i>F. Meier</i> ; <i>J. Paavonen</i> ; <i>J.D. Poveda</i> ; <i>J.A.R. Van Den Hoek</i> , France	22306
624	Comparison of the amount of HPV 16 DNA in cervicovaginal secretions of HIV-infected and uninfected women, using quantitative competitive-polymerase chain reaction (QC-PCR) <i>Thomas Wright*</i> ; <i>X.W. Sun</i> ; <i>T.V. Ellerbrock</i> ; <i>Chiasson</i> , USA	22311

B47 Grand Rounds: Clinical Case Studies

Chairs: David Chipanta, Michel P. Glauser

Venue: Arena

Time: 15.00–17.00

625	Case presentations <i>Amalio Telenti</i>
626	Virologic failure <i>Joep Lange</i>
627	Treatment complications <i>Robert Schooley</i>
628	A case of HIV-infection in the developing world <i>Sin Yew Wong</i>
629	Natural history of HIV-associated disease under HAART <i>Diane Havlir</i>

		G	P
C48	Bridging Session: Microbicides: Towards a New Paradigm		
Chairs: Lori Heise, Joseph Perriens			
Venue: Session Hall V			
Time: 15.00–17.00			
630	Economic and marketing issues <i>Lieve Fransen</i>		
631	State-of-the-art: clinical research <i>Zeda Rosenberg</i>		
632	Pre-clinical overview: what possibilities exist <i>Mark Wainberg</i>		
633	Case study for political advocacy: Zimbabwe <i>Priscilla Misihairabwi</i>		
634	Discussant: trials <i>Gita Ramjee</i>		
635	Discussant: consumer perspective <i>Kanokwan Gaye Tharawan</i>		
636	Discussant: government perspective <i>Debra Birnkrant</i>		
		G	
D45	Implications of New Treatments at Individual and Population Level		
Chairs: Enzio Dos Santos Filho, C. Perez			
Venue: Session Hall I			
Time: 15.00–17.00			
637	AIDS, virtually normal now? Protease inhibitors and the end of consensus <i>Meuristyn Horton, UK</i>	44183	
638	Do people fail drugs, or do drugs fail people? The discourse of "adherence" <i>Agnes Harley*; J.D. Davids; J.M. Maskovsky; J.S. Shull, USA</i>	34212	
639	T.H.E. (Tools for Health and Empowerment) course: A unique disease management program <i>W. David Hardy*; Ebere Igboke; M.M.L. Rice; K. Anastos; E.F. Igboke; R. Torres; P.J. Welch; S.D. Goodwin, USA</i>	34236	
640	The impacts of combination therapies on the lives of people with HIV <i>Peter Weaterburn*; W. Anderson; F.C.I. Hickson; P.G. Keogh, UK</i>	24260	
641	Treatments, intimacy and disclosure in the sexual practice of HIV-infected adults in Australia <i>Michael Bartos*; D. Ezzy; K. McDonald; D. O'Donnell; R. de Visser, Australia</i>	23402	
642	HIV/AIDS preventive attitudes and behaviour of French and Swiss gay men in the era of new treatments. A comparison of two national surveys <i>Phillipe Adam*; F. Moreau-Gruet; F. Hamers; M.C. Delmas; J.B. Brunet; F. Dubois-Arber, France</i>	34107	
643	HAART, attitudes, and risk behaviour among serodiscordant male couples <i>Robert H. Remien*; G. Wagner; A. Carballo Dieguez; C. Dolezal, USA</i>	14136	
644	New therapies for HIV and sexual risk behaviour among gay men in London, UK <i>Graham Bolding*; Jonathan Elford; L. Sherr; M. Maguire; J. Elford, UK</i>	23106	

		P
D46	Resource Mobilisation: Where Will the Money Come From?	
Chairs: Sally Cowall, Sofia Mukaso-Monico		
Venue: Session Hall II		
Time: 15.00–17.00		
645	Sustainability beyond donor aid <i>Soledad Atayan, Philippines</i>	44220
646	The Global Business Council on HIV/AIDS (GBC) <i>Jose LLados*; Ben Plumley; J. Hussey, UK</i>	44223
647	Amounts, patterns and trends of national and international financing of the response to HIV/AIDS in developing countries, 1996–1997 <i>Daniel Tarantola*; G. Ernberg, USA</i>	44232
648	European funding for HIV in the developing world <i>Jan Prank</i>	
649	North American Funding for HIV in the developing world <i>Steve Morin</i>	
650	Funders concerned about AIDS on philanthropic funding <i>Paul di Donato</i>	
651	A unique Zululand industry joint venture response to the needs of employees with HIV/AIDS <i>Jennifer Rogers, South Africa</i>	44221

Track A: Basic Science

- 41101 Interactions of secretory IgA with HIV-1 gp120: Potential pitfalls of anti-HIV ELISA using saliva
*Susan Jackson**; S.J. Prince; R. Kulhavy; J. Mestecky, USA
- 41102 HIV-screening with the Elecsys automated analyser: Combined testing for anti-HIV and HIVAg within 18 minutes
*Frédéric Donie**; B. Upmeier; E. Hoess; E. Faatz, Germany
- 41103 Detection of memory T cells in HIV+ individuals: Cytokine producing lymphocyte precursors (CPLp)
*Kendall A. Smith**; G. Chiochia; F. Pilaro; E.L. Jacobson; R. Emert, USA
- 41104 Universal peptide for detection of HIV-1 group M and group O infections in rapid immunoassay
*Afzal Chowdhury**; J.M. Lovchik; M.A. Childs; D. Bernstein, USA
- 41105 Evaluation of a locally produced particle agglutination assay for detection of antibodies to HIV-1
*Wilfred James Njoroge**; C.W. Mutura; W.A. Mwangi; N. Sakagami; K. Kakimoto; P.M. Tukei; T. Kurimura, Japan
- 41106 Murex HIV-1.2.O is a highly sensitive and specific assay for antibodies to HIV-1/M, HIV-1/O and HIV-2
*Richard Bristow**; T. Carter; K. Francis; J. Lovell; B. Rodgers; D. Trotter; P. Weston, UK
- 41107 Detection of HIV-1 Subtypes by a new rapid immunochromatographic test
*Hiroyasu Arai**; S. Devare; T. Kosaka; K. Takeda, Japan
- 41108 Validation study of HIV testing in urine samples
*David Mabey**; John Chungalucha; B. West; D. Ross; R. Balira; J. Todd; T. Boerma; D. Mabey, UK
- 41109 Predictors of HIV-infection among professional blood donors with Western Blot Indeterminate results (WBI)
*Usha K. Baveja**; D. Chattopadhyay; R.K. Aggarwal; V. Doda; S. Kumari; J. Sokhey, India
- 41110 HIV antibody activity measurement how to distinguish primoinfected from old infected patients using one ELISA test adapted to AXSYM Automate
*Christopher Paxan**; A. Lemeur; B. Evreux; S. Kouyoumdjian; J-M. Chenebault; F. Lunel
- 41111 Identification of a new virus-associated epitope inducing antibody responsible for the non-progression to AIDS
*Pascale Galea**; C.R. Steinhart; P. Willem; N. Profizi; C. Lecontel; J.C. Chermann, France
- 41112 In vitro HIV-1 antibody induction. Testing of the "Shiloo Tube
*Carmen Soler Claudin**; C. Gomez Palomino; T. Jehuda-Cohen, Mexico
- 41113 A new generation of HIV-diagnostic assay: Results of the evaluation of the Enzymun-Tests HIV combi
*Eluke Faatz**; F. Donie; W. Melhior; B. Upmeier; C. Seidel, Germany
- 41114 Performance of calypte HIV-1 urine EIA in three us populations
*Dean Schoer**; V. Mitteco; T. Gottfried; M. Kanar, USA
- 41115 Performance of an HIV-1, HIV-2 and HIV-1 group O immunoassay on the Abbott ARCHITECT 2000 analyzer
*William Black**; S. Stewart; A. Hoffman; J. Probstko; L. Xu, USA
- 41116 A new approach to flow cytometry-based CD4 T-cell enumeration for absolute and percentage values
*Michèle Bergeron**; F.F. Mandy; T. Ding; S. Phaneuf, Canada
- 41117 Sensivity evaluation of Vironostika Uni-Form II plus O with samples from Thailand
Thippawan Chuenchitra, Thailand
- 41118 HIV-screening with the Elecsys* automated analyser: Testing for HIVAg within 18 minutes with a sensitivity of 3 pg/ml
*Urban Schmitt**; D. Schlieper; B. Upmeier; W. Melchior; E. Faatz, Germany
- 41119 Anti HIV1/2 mass testing, what should be done?
*Alexandre M. Oliveira**; C.C. Hofling; M.C. Ramos; S.A.A. Chaves, Brazil
- 41120 Rapid, 3rd generation one-step immunoassay for HIV antibodies, useful in developing countries
Jesus Benitez; O. Ganzo; J. Rivero; J. Gavilondo, Cuba
- 41121 Seroprevalence of HIV-infection among street children in Maiduguri
*Edemeng D. Okpudo-Itata**; T.O. Harry; M. Bulterys; A. Abimiku, Nigeria
- 41122 Sensitivity of HIV-1 group M Western blot for the confirmation of HIV-1 group O infections, according to different interpretation criteria
*Charlotte Ngansop**; Seraphin Kuate; L. Zekeng; M. Kengne; L. Kaptue, Cameroon
- 41123 Prevalence and control of STDs/HIV among commercial sex workers (CSW)
*Jyotsna Shrestha**; V.L. Gurubacharya, Nepal
- 41124 Modifications in the DTH reaction in HIV-infected individuals
Kamen Plochev, Bulgaria
- 41125 Evaluation of a fast method (HIVSAV*) for serologic diagnosis of HIV-1 e 2
*Draurio Barreira**; G. Silva; H.M.V. Oliveira; Y. Bravin, Brazil
- 41126 Immunological monitoring in HIV-infection
*Yuri Mitin**; E.I. Zmushko; A.N. Malkov, Russia
- 41127 Field evaluation of the HIV-1 Amplicor Monitor and NucliSens quantitative HIV-1 RNA PCR assay in persons infected with HIV-1 subtype A in Abidjan, Côte d'Ivoire
*John Nkenga Song**; M. Kalou; C. Bile; M.Y. Borget; M. Morokro; E.R. Ekpini; P. Ghys; A.E. Greenberg; S.Z. Wiktor, Côte d'Ivoire
- 41128 Comparative evaluation of amplicor HIV-1 monitor with added primer set with quantiplex v2.0 HIV RNA assay and the nuclisens for quantitation of HIV-1 RNA in a Thai study population, primarily infected with subtype E
*Sasiwimol Ubolyam**; K. Ruxrungtham; G.J. Weverling; C. Ungsidthapand; J. Lange; D. Cooper; P. Phanuphak, Thailand
- 41129 High throughput assay for sensitive detection of HIV-1 RNA of diverse origins, including type O strains
*Cristina Giachetti**; D. Kolk; J. Dockter; J.P. Knowlton; R. Wang; S. Hotelling; S. McDonough, USA
- 41130 Sensitivity, linear range and performance of HIV-1 subtypes of the COBASAMPLICOR HIV-1 monitor test
*Cynthia Pletcher**; D. De Bonville; J. Wang; K. Lavallee; A. Chutoransky; K. Arch; A. Wang, USA